BC
NPCE icon

Birchview Capital’s Neuropace NPCE Stock Holding History

Birchview Capital’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,442
Closed -$183K – 76
2025
Q2 		$183K Hold
16,442
– – 0.18% 59
2025
Q1 		$202K Buy
16,442
+6,442
+64% +$80.6K 0.18% 53
2024
Q4 		$112K Buy
+10,000
New +$86.9K 0.09% 63

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KLP
Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Birchview Capital's NPCE Position: Q3 2025 in Review

Birchview Capital sold out of Neuropace (NPCE) in Q3 2025, closing a stake of 16,442 shares — an estimated $183K sold.

Birchview Capital first reported a position in NPCE in Q4 2024 and held it in 3 quarters. The position peaked at $202K in Q1 2025. 80 funds tracked by Wall St. Rank hold NPCE as of Q3 2025.

  • Birchview Capital reported no remaining Neuropace position as of Q3 2025 after selling out during the quarter.
  • Birchview Capital sold 16,442 Neuropace shares in Q3 2025, an estimated $183K.
  • Birchview Capital first reported a position in Neuropace in Q4 2024 and held it in 3 quarters.
  • Birchview Capital's Neuropace position peaked at $202K in Q1 2025.
  • 80 funds tracked by Wall St. Rank held Neuropace as of Q3 2025.

Based on Birchview Capital's 13F filing for Q3 2025, filed 13 Nov 2025.